Previous Close | 11.05 |
Open | 11.00 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 800 |
Day's Range | 10.27 - 11.00 |
52 Week Range | 6.40 - 15.60 |
Volume | |
Avg. Volume | 579,803 |
Market Cap | 654.264M |
Beta (5Y Monthly) | 0.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.59 |
Earnings Date | Oct 30, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 28.13 |
Subscribe to Yahoo Finance Plus to view Fair Value for DYN
After dropping to 52-week lows, the markets have been rallying lately. That has traders and investors scrambling for cheap stocks under $20 to buy. This bullish sentiment comes amidst a backdrop of sticky inflation and interest rates that are likely to remain elevated for some time. And another factor is the geopolitical events which include real concerns about an escalation of war in the Middle East. For all those reasons, it may not be time to call an all-clear on the market. Nevertheless, wit
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November: Stifel 2023 Healthcare Conference, fireside chat on Tuesday, November 14, 2023 at 4:45 p.m. ET in New York Piper Sandler 35th Annual Healthcare Confe
Company's cash position remains strong, R&D expenses increase, and net loss widens